Clinical Trial Update: Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD [Phase 2]

View source ↗

Summary

This update reports on a Phase 2 trial evaluating the efficacy and safety of AL-001 ophthalmic injection in wet age-related macular degeneration. The study is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• AL-001 Ophthalmic Injection (AL-001)

Snippet

Sponsor: Beijing Anlong Biopharmaceutical Co., Ltd. | Conditions: Wet Age-related Macular Degeneration (wAMD) | Phase 2 | Status: NOT_YET_RECRUITING